Printer Friendly

NORTH AMERICAN BIOLOGICALS ELECTS DAVID J. GURY CEO AND CHAIRMAN FOLLOWING RETIREMENT OF THOMAS HALASZ

 NORTH AMERICAN BIOLOGICALS ELECTS DAVID J. GURY CEO AND CHAIRMAN
 FOLLOWING RETIREMENT OF THOMAS HALASZ
 MIAMI, April 3 /PRNewswire/ -- North American Biologicals, Inc. (NASDAQ: NBIO) ("NABI") today announced that David J. Gury, president and chief operating officer of the company since 1984, has been elected chief executive officer, president and chairman of the board of directors. Gury succeeds Thomas Halasz, who has retired following eight years as NABI's chairman and CEO. This management succession follows the completion earlier this week of a major transaction in which NABI significantly changed its equity structure, repurchased a controlling block of stock, and acquired an international plasma-based biologicals business.
 The company also announced that Richard A. Harvey, Jr., president of BNY Associates Incorporated, has been elected to the NABI board of directors. Harvey has more than 15 years of experience in investment banking, and formerly served as senior vice president at Shearson Lehman Brothers. BNY Associates, the investment banking subsidiary of The Bank of New York, acted as financial advisor and placement agent for NABI in the recently completed $27 million transaction.
 "In recent years, we have positioned NABI for growth in a number of attractive geographic and product markets where our company's expertise and reputation give us strong competitive advantages," said David J. Gury, NABI's newly elected chairman and chief executive officer. "At this point , we have both the operating capability and the financial resources to implement our ambitious plans for sales and earnings growth throughout the 1990's," he said.
 "In coming months, we intend to further enhance the company's executive strengths in certain key areas. As a first step towards this objective, we welcome the strategic skills that Rich Harvey will add to our board," Gury noted. "At the same time, we thank Tom Halasz for his many contributions to the company, and wish him well in all his future endeavors."
 Gury has more than 20 years experience in the plasma products industry. Prior to joining NABI as president and chief operating officer in 1984, he served for 22 years with Abbott Laboratories and Alpha Therapeutic Corporation in marketing operations and finance positions. Gury will be elected to the Board of the American Blood Resources Association (ABRA), an organization representing over 100 corporations worldwide, dedicated to ensuring an adequate and safe supply of blood and blood derivatives for medical, pharmaceutical and scientific use.
 North American Biologicals, Inc. headquartered in Miami, is the world's largest independent provider of human blood plasma elements to the health care industry, one of the largest AIDS screening laboratories in the United States, and a leading supplier of control products used to ensure accuracy in blood testing laboratories.
 -0- 4/2/92
 /CONTACT: David J. Gury or Alfred J. Fernandez of North American Biologicals, Inc. 305-628-0080, or Marcia Kean or Lori Martin of Feinstein Partners, 617-577-8110, for North American Biologicals/
 (NBIO) CO: North American Biologicals, Inc. ST: Florida IN: MTC HEA SU: PER


TM -- NE004 -- 4711 04/03/92 08:38 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 3, 1992
Words:494
Previous Article:GARNET ANNOUNCES PRODUCTION START-UP AND NEW BLOCK IN COLOMBIA
Next Article:MERCANTILE STORES COMPANY ANNOUNCES COMMENCEMENT OF TENDER OFFER
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS AWARDED $9 MILLION IN FEDERAL CONTRACTS FOR AIDS SCREENING AND OTHER BLOOD TESTING AND PRODUCTS
FDA CLEARS NABI'S QC-HEPATITIS PRODUCT FOR MARKETING
NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1991 RESULTS
NORTH AMERICAN BIOLOGICALS COMPLETES $27 MILLION TRANSACTION
NORTH AMERICAN BIOLOGICALS, INC. EXPANDS MANAGEMENT TEAM; APPOINTS PINYA COHEN FROM NIH AND GEORGE BINGHAM FROM BAXTER
NORTH AMERICAN BIOLOGICALS, INC. AWARDED $45 MILLION EUROPEAN CONTRACT: PLASMA ORDER IS LARGEST IN NABI'S HISTORY
NORTH AMERICAN BIOLOGICALS RECEIVES FDA LICENSE FOR NEW BIOMEDICAL CENTER - $1.7 MILLION IN PLASMA SHIPMENTS FROM OKLAHOMA SITE UNDERWAY
NORTH AMERICAN BIOLOGICALS COMPLETES ACQUISITION OF MAJOR PLASMA COMPANY
NORTH AMERICAN BIOLOGICALS, INC. LAUNCHES EUROPEAN OPERATIONS WITH ACQUISITION OF GERMAN PLASMA FACILITIES
NORTH AMERICAN BIOLOGICALS, INC. AND UNIVAX BIOLOGICS, INC. COMPLETE MERGER, CREATING NEW FIRST-TIER BIOPHARMACEUTICAL COMPANY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters